Janssen Pharmaceutica Nv

Greta Constantia Peter Vanhoof

Gregor James MacDonald

Michiel Luc Maria Van Gool

Joannes Theodorus Maria Linders

José Manuel Bartolomé-Nebreda

Louis Jozef Elisabeth Van Der Veken

Susana Conde-Ceide

Libuse Jaroskova

Ronaldus Arnodus Hendrika Joseph Gilissen

María Luz Martín-Martín

Gustaaf Henri Maria Willemsens

Joaquin Pastor-Fernández

Andrés Avelino Trabanco-Suárez

Jérôme Emile Georges Guillemont

José Ignacio Andrés-Gil

Christophe Francis Robert Nestor Buyck

Maarten Vliegen

Frederik Jan Rita Rombouts

Peter Jacobus Johannes Antonius Buijnsters

Antonius Adrianus Hendrikus Petrus Megens

Óscar Delgado-González

Carina Leys

Johan Erwin Edmond Weerts

Meri De Angelis

Sergio-Alvar Alonso-de Diego

Guy Maurits R Bormans

Xavier Jean Michel Langlois

Stijn Wuyts

Sofie Jeanne Leopoldine Celen

Kelly Ann Swinney

Christophe Francis Robert Nester Buyck

José Ignacio ANDRÉS-Gil

ÓScar Delgado-GONZÁLEZ

The present invention relates to novel 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives as inhibitors of phosphodiesterase 2 (PDE2) and to a lesser extent of phosphodiesterase 10 (PDE10) or as inhibitors of both, phosphodiesterases 2 and 10. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, or disorders in which both PDE2 and PDE10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases. The present invention also relates to radiolabelled compounds which may be useful for imaging and quantifying the PDE2 enzyme in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, to processes for preparing such compounds and compositions, to the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.

1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives

The present invention relates to novel imidazo[1,2-a]pyrazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases

The present invention relates to novel imidazo[1,2-]pyridazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, to the use of such compounds or pharmaceutical compositions for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases.

Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors

Adamantyl acetamides as 11-&#x3b2; hydroxysteroid dehydrogenase inhibitors

the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n represents an integer being 1 or 2; Rand Reach independently represents hydrogen Calkyl, NRR, Calkyloxy; or Rand Rtaken together with the carbon atom with which they are attached form a Ccycloalkyl; and where n is 2, either Ror Rmay be absent to form an unsaturated bond; Rrepresents a Ccycloalkyl, preferably selected from cylo-octanyl and cyclohexyl or Rrepresents a monovalent radical having one of the following formulae  

Adamantyl acetamides as 11-beta hydroxysteroid dehydrogenase inhibitors

Growing community of inventors

Zoersel, Belgium

Greta Constantia Peter Vanhoof